The American College of Cardiology (“ACC”) and Acarix have signed a strategic collaboration agreement with the goal to develop a clinical framework for the use of cardiovascular acoustic AI-based technology in the United States, the world’s largest market for cardiovascular care.
Within the scope of the collaboration, ACC will provide clinical and scientific expertise to Acarix with the intent to assess the utility and role for acoustic AI-based technology in the US and develop a clinical framework for use of CADScor®System in upstream cardiac diagnostics.
“The agreement with ACC is the most important strategic relationship we have entered so far. Our mission is to make the CADScor®System standard of care to aid rapid chest pain diagnosis and we believe the collaboration with the ACC will help us accelerate the use of our novel technology.” comments Helen Ljungdahl Round, President and CEO of Acarix.
ACC is a US-based nonprofit medical association established in 1949 with more than 56,000 members. ACC issues clinical practice guidelines, provides professional medical education, operates national data registries, and manages data standards and national quality initiatives with the aim to transform cardiovascular care and improve heart health.
Each year, millions of Americans seek healthcare consultations for chest pain. Acarix recently entered the US market following FDA De Novo clearance for its acoustic AI-based CADScor®System to help rapidly and accurately rule-out significant obstructive coronary artery disease in patients with chest pain. The CADScor®System is covered by a dedicated CPT III code 0716T issued in 2021 and effective from July 1, 2022.